The option of producing multimeric PSMA SMOL conjugates offers the possibility of further adjusting the pharmacological properties of PSMA SMOL-TTC, such as tumor uptake rate, salivary gland uptake, and pharmacokinetic profile. This evidence concerns the gene FOLH1 and neoplasm.